ScoreComparison
Why is Noile-Immune Biotech, Inc. ?
1
Poor Management Efficiency with a low ROE of 0%
- The company has reported losses. Due to this company has reported negative ROE
2
Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%
3
Flat results in Jun 25
4
Risky - Negative EBITDA
- The stock is trading risky as compared to its average historical valuations
- Over the past year, while the stock has generated a return of -14.46%, its profits have fallen by -23%
5
Below par performance in long term as well as near term
- Along with generating -14.46% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Noile-Immune Biotech, Inc. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Noile-Immune Biotech, Inc.
-12.35%
-0.85
46.43%
Japan Nikkei 225
27.55%
0.98
25.79%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-47.10%
EBIT Growth (5y)
-30.65%
EBIT to Interest (avg)
-844.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0.06
Tax Ratio
0.32%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.61
EV to EBIT
-2.84
EV to EBITDA
-2.84
EV to Capital Employed
140.39
EV to Sales
386.67
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-4938.52%
ROE (Latest)
-19.27%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend10What is working for the Company
NET SALES(HY)
At JPY 4.29 MM has Grown at 65.64%
NET PROFIT(HY)
Higher at JPY -411.67 MM
RAW MATERIAL COST(Y)
Fallen by 0% (YoY
OPERATING PROFIT(Q)
Highest at JPY -170.96 MM
0What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Here's what is working for Noile-Immune Biotech, Inc.
Net Sales
At JPY 4.29 MM has Grown at 65.64%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (JPY MM)
Net Profit
Higher at JPY -411.67 MM
than preceding 12 month period ended Jun 2025MOJO Watch
In the half year the company has already crossed Net Profit of the previous twelve months
Net Profit (JPY MM)
Operating Profit
Highest at JPY -170.96 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (JPY MM)
Raw Material Cost
Fallen by 0% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
